Bounce-Back Kings: 9 Stocks Up More Than 30% in the Past Month
These nine stocks have bounced back from sell-offs in August, and their share prices are more than 30% higher than a month ago.
Clearwire (NASDAQ: CLWR) shares are trading more than 60% higher than a month ago, despite pulling back more than 17% in the past week. Recent buyout rumors and the halt of the AT&T (NYSE: T) and T-Mobil deal helped lift shares. The wireless broadband provider has a market cap of $2.3 billion and it has been posting quarterly losses since before the recession. Year to date, the stock has underperformed partner Sprint Nextel (NYSE: S) and the broader markets.
Eastman Kodak (NYSE: EK) is up more than 36% in the past month, despite a more-than 11% pullback in the past week. The venerable film company has been looking for a buyer for at least 1,000 of its digital-imaging patents, which could fetch as much as $3 billion. Kodak's market cap is only $758.4 million. And at $2.82 a share, the stock is well off its 52-week high of $5.95 despite the recent run up. Short interest is more than 30% of the float.
Idenix Pharmaceuticals (NASDAQ: IDIX) is up more than 44% in the past month, as well as up more than 112% in the past year. Brookside Capital Management recently acquired a 9 million-share position in this developer of viral disease treatments, even though its IDX184 is still in phase II trials. Idenix's market cap is $576.9 million and its long-term EPS growth forecast is 29.0%. But the stock has underperformed competitor Pharmasset over the past six months.
KiOR (NASDAQ: KIOR) shares are selling about 37% higher than a month ago and are up more than 9% in the past week. This Texas-based renewable fuels producer went public earlier this summer. One so-called beneficial owner (more than 10% stake) has been buying shares since the IPO. The market cap is $1.6 billion. KiOR has a long-term EPS growth forecast of 34.0%. The stock performance has been in line with the broader markets since the IPO.
Optimer Pharmaceuticals (NASDAQ: OPTR) is up more than 65% from a month ago, rising almost 30% in the past week. The California biotech company said yesterday that it sold $3.9 million of its antibiotic Dificid during the six weeks since its launch. The CEO bought 25,000 shares recently. The market cap is $596.0 million and the mean price target is 24% higher than the current share price. The stock is climbing again toward the 52-week high of $14.74 a share in June.
Pharmasset (NASDAQ: VRUS) is up about 32% from a month ago; the price is up more than 20% just in the past week and near the 52-week high of $79.24. Last week, this biotech company announced encouraging results from a study of a potential hepatitis C treatment. Based in Princeton, N.J., Pharmasset has a market cap of $5.8 billion and a long-term EPS growth forecast of 20.0%. Year to date, the stock has outperformed competitors such as Idenix and Merck (NYSE: MRK).
TiVo (NASDAQ: TIVO) shares are trading almost 37% higher than a month ago and last week closed above $11 for the first time since November. Last week TiVo announced a joint venture with Spain's largest cable provider and also the addition of a Harvard business professor to its board. TiVo's market cap is $1.3 billion and its long-term EPS growth forecast is 40.0%. Year to date, the stock has outperformed AT&T and Sony (NYSE: SNE).
Universal Display (NASDAQ: PANL) shares are trading about 67% higher than a month ago, and up about 134% from a year ago. While earnings are expected to be negative for 2011, the consensus forecast calls for earnings of 86 cents per share in 2012. Goldman Sachs recently upgraded the stock. The flat panel display maker has a market cap of $2.3 billion and a long-term EPS growth forecast of 24.5%. The stock has outperformed competitor AU Optronics (NYSE: AUO) and the Nasdaq year to date.
Zillow (NASDAQ: Z) is up more than 40% from a month ago, including nearly a 10% rise in the past week. This Seattle-based online real estate information marketplace went public in July and reported its first profitable quarter in August, with revenues that doubled year over year. The market cap is $1.0 billion and the long-term EPS growth forecast is 78.3%. The stock has outperformed Dunkin Brands (NASDAQ: DNKN) and LinkedIn (NYSE: LNKD), which also had recent IPOs.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.